The ceramide synthase 4 (CERS4) antibody is a research tool designed to detect and study the CERS4 protein, a key enzyme in sphingolipid metabolism. CERS4. also known as longevity assurance gene 3 (LASS3), is one of six isoforms in the ceramide synthase family (CERS1-6). It specifically catalyzes the synthesis of C18–C20 acyl-chain ceramides, which are critical components of cell membranes and signaling molecules involved in apoptosis, differentiation, and stress responses. CERS4 is highly expressed in skin and testes, where it contributes to epidermal barrier function and spermatogenesis.
Antibodies targeting CERS4 are typically generated using immunogens derived from conserved regions of the human or mouse CERS4 protein. These antibodies enable researchers to investigate CERS4 expression patterns, localization, and regulatory roles via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of CERS4 has been implicated in skin disorders (e.g., psoriasis), metabolic syndromes, and cancer progression, making its study clinically relevant. For example, reduced CERS4 levels are linked to impaired keratinocyte differentiation, while overexpression in certain cancers may influence tumor survival. The development of specific and validated CERS4 antibodies thus supports ongoing exploration of sphingolipid biology and its therapeutic applications.